An Open label study to evaluate the long term safety and efficacy of CSL312 (garadacimab) in the prophylactic treatment of hereditary angioedema (NCT04739059)
CSL312-3002
This trial is No longer recruiting
Registration number NCT04739059
Program & service
This trial is being run with the Heart & Lung service, and as part of the Respiratory program.
Trial phase
Phase 3
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Associate Professor Celia Zubrinich
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR